You are on page 1of 1

Kiarah Eunize P.

Gica
2E-MT

Hepatitis C Virus or HCV, a viral infection has been subjected into a study with the
goal of eradication of the said virus. Pharmacogenomics playing a big role in
understanding the virus’ prognosis and pathogenisis leading to a more accurate anti-virus
treatments. IL28B or interleukin 28B genotypes are renowned and greatly recognized by
many researches as it is a gene involved in immuno responses on certain viruses
including HCV which is why it is the main focus in the article.

IL28B can predict the treatment response during earlier stages of the virus, making it
a so-called breakthrough. It is now treated as the main tool for the diagnosis and
management of HCV patients. Compared to pegylated-interferon α and ribvirin
combination therapy, IL28B is the more likely treatment for HCV-infected patients as
pegylated-interferon α and ribvirin combination therapy can only be obtained by half a
hundred percent of the patients infected.

However, even with the various positive effects IL28B possesses, the biological
pathway which relates to treatment induced HCV clearances is still undetermined. Still,
through IL28B, strategies of prevention of various diseases can be formulated and which
can improve the life quality of a person as it does in treatment of HCV. As a result, it is
not far off that the possibility of development of effective and newly generated drugs is
just around the corner, especially with the influence of IL28B. For now, the main goal
would be the ideal treatment of chronic HCV infection that if appropriate in a way the
patient to be treated won’t encounter side effects and harmful effects.